CIRCLE
Circle, a global financial technology firm and the issuer of USDC and EURC, has today announced that it has become the first global stablecoin issuer to achieve compliance with the European Union's landmark Markets in Crypto-Assets (MiCA) regulatory framework.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701820713/en/
Circle's Coralie Billmann, Jeremy Allaire, Patrick Hansen | Photo Credit: Tristan Montalbot
This achievement was enabled by the company’s attainment of an Electronic Money Institution (EMI) license (’agrément en qualité d'établissement de monnaie électronique) from the Autorité de Contrôle Prudentiel et de Résolution (ACPR), the French banking regulatory authority. With this license, both USDC and EURC are now being issued in the EU in compliance with MiCA’s regulatory obligations for stablecoins or e-money tokens, which took effect yesterday, according to the law today and subject to potential clarifications on the interpretation of the law by the European Commission.
As part of attaining compliance with this comprehensive regulatory regime, Circle Mint is officially available for business customers in Europe. Equipped with local banking capabilities, Circle Mint France provides near-instant and cost-effective access to mint and redeem USDC and EURC throughout the European market.
“Since our founding, Circle has sought to build durable, compliant, and well-regulated infrastructure for stablecoins, and our adherence to MiCA, which represents one of the most comprehensive crypto regulatory regimes in the world, is a huge milestone in bringing digital currency into mainstream scale and acceptance,” said Jeremy Allaire, Co-Founder and Chief Executive Officer at Circle. “By working closely with French and EU regulators, we are now able to offer both USDC and EURC as fully-compliant dollar and euro stablecoins to the European market, unlocking the enormous potential of digital assets to transform finance and commerce.”
"Achieving MiCA compliance through our French EMI license is a significant step forward, not just for Circle, but for the entire digital financial ecosystem in Europe and beyond," said Dante Disparte, Chief Strategy Officer and Head of Global Policy at Circle. "As digital assets become increasingly integrated into the mainstream financial landscape, it is essential that we establish robust, transparent frameworks to promote trust and adoption. Today’s announcement further reinforces our commitment to building a more inclusive, compliant future for internet finance."
"Circle's success in obtaining this license is the result of close collaboration over many months between the regulatory teams in charge of ACPR authorizations and the Circle France team," said Coralie Billmann, Managing Director of Circle France.
Of the top 10 stablecoins by market capitalization, only USDC is currently MiCA-compliant. This milestone underscores Circle's commitment to regulatory compliance for dollar and euro stablecoins. The company's proactive approach to meeting high standards of security, transparency and oversight will help drive the mainstream adoption of regulated digital currencies.
About Circle
Circle is a global financial technology firm that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. Circle is the issuer of USDC and EURC - highly liquid, interoperable, and trusted money protocols on the internet. Circle’s open and programmable platform and APIs make it easy for organizations to run their internet-scale business, whether it is making international payments, building globally-accessible Web3 apps, or managing their internal treasury. Learn more at https://circle.com.
Disclaimer
This marketing communication is issued by Circle Internet Financial Europe SAS, a licensed Electronic Money Institution and registered Digital Assets Services Provider in France. White Papers relating to electronic money tokens that we issue in the European Economic Area (EEA) ("EMT") are published and available on our website. Holders of EMT have the right of redemption against the issuer at any time and at par value. Contact: Web: http://www.circle.com | Email: EEA-Customer-Support@circle.com | Phone number : +33 (1) 59000130
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701820713/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AppLogic Networks Announces Strategic Rollout of Industry-First, Comprehensive 400GE Networking Enablement Across Virtual and Appliance-Based Network Domains to Meet Explosive Data Growth8.7.2025 15:00:00 CEST | Press release
Innovative solution represents cost-efficient, streamlined offering with multiple deployment options, catering to both physical networking appliances and virtual infrastructure, while delivering superior performanceEnables Tier 1 and Tier 2 fixed and mobile network operators to accelerate deployment, simplify maintenance, and scale without the need for massive infrastructure investment AppLogic Networks, a leader in application classification and high-performance software-based networking solutions, today announced a significant expansion of its portfolio to support 400 Gigabit Ethernet (400GE) across both traditional appliance-based and virtual infrastructure domains. This move comes as telecom and service providers worldwide face unprecedented growth in network traffic, fueled by 4K/8K streaming, cloud gaming, AI workloads, and IoT proliferation. As part of this expansion, AppLogic Networks now offers comprehensive 400GE enablement and interoperability in its flagship data plane plat
Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release
Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M
Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release
Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom